A Study to Determine the Effect of CT3001 in Patients with Advanced Solid Tumors
Phase 1
Recruiting
- Conditions
- Solid Tumor, AdultColorectal CancerPancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-04
- Lead Sponsor
- Crossignal Therapeutics, Inc.
- Target Recruit Count
- 78
- Registration Number
- NCT06598007
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath